Every Tuesday, we break down 10 of the most significant biopharma stories and buzzworthy clinical trial breakthroughs from the previous week. The podcast highlights major Phase 2 and Phase 3 trial results, breakthrough therapies, biotech innovations, FDA updates, and emerging treatments shaping the future of medicine. From obesity and cancer to autoimmune disease, neurodegeneration, cardiovascular disease, diabetes, and rare genetic disorders, each episode delivers a fast, accessible look at the data, discoveries, and therapies driving the next generation of healthcare.
Last Week in Biomedicine
Claim This Podcastby TrialBreaks
17 episodes
Updated Daily
Accepts GuestsHas Sponsors
Podcast Overview
Every Tuesday, we break down 10 of the most significant biopharma stories and buzzworthy clinical trial breakthroughs from the previous week. The podcast highlights major Phase 2 and Phase 3 trial results, breakthrough therapies, biotech innovations, FDA updates, and emerging treatments shaping the future of medicine. From obesity and cancer to autoimmune disease, neurodegeneration, cardiovascular disease, diabetes, and rare genetic disorders, each episode delivers a fast, accessible look at the data, discoveries, and therapies driving the next generation of healthcare.
Language
🇺🇲
Publishing Since
5/12/2026
1 verified contact email on file for Last Week in Biomedicine
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
July 9, 2026
Last Week in Biomedicine | Jun 29–Jul 3 | Part 2 of 2: Baby Pompe Disease Trial, DLBCL Combo Win
<p>Part 2 covers three more standout stories from the same week: a Phase 3 trial that gives babies with a devastating enzyme disease a fighting chance, a first-of-its-kind cell therapy approved to make bone-marrow transplants safer, and a new lymphoma combination that could give aggressive-blood-cancer patients another option after other therapies fail.</p><p><br></p><p>In Part 2 we cover:</p><p>4. Sanofi — Nexviazyme (avalglucosidase alfa) for infantile-onset Pompe disease (Phase 3)</p><p>5. Orca Bio — Tregzi (allogeneic regulatory T-cell immunotherapy) for adults with blood cancers undergoing matched-donor bone-marrow transplant (FDA approval)</p><p>6. Genmab / AbbVie — Epkinly (epcoritamab) plus lenalidomide for relapsed or refractory diffuse large B-cell lymphoma (Phase 3)</p><p><br></p><p>What could this mean for patients? The Sanofi Baby-COMET result is the most emotionally consequential story of the week. Infantile-onset Pompe disease is usually fatal in a baby's first year without treatment, and a Phase 3 trial hitting every primary and secondary endpoint means more infants may reach toddlerhood breathing on their own — an outcome that was unimaginable a generation ago.</p><p><br></p><p>Catch Part 1 if you missed it. Subscribe at TrialBreaks.com.</p><p><br></p><p>#biomedicine #clinicaltrials #science #Pompedisease #enzymereplacement #rarediseases #genetherapy #celltherapy #bonemarrowtransplant #GVHD #hematology #lymphoma #DLBCL #bispecificantibody #immunotherapy #oncology</p>
July 7, 2026
Last Week in Biomedicine | Jun 29–Jul 3 | Part 1 of 2: CRISPR for Toddlers, KRAS Lung Cancer Win
<p>CRISPR gene editing crossed a major line this week: the FDA now allows Casgevy — the first CRISPR therapy of any kind — for children as young as 2 with sickle cell disease, meaning we can potentially prevent a lifetime of pain crises and organ damage instead of treating them after the fact. Part 1 also digs into a rare kind of trial where a new lung cancer drug takes on the already-approved competition, and a New England Journal of Medicine paper on the first oral pill for a form of childhood dwarfism.</p><p><br></p><p>In Part 1 we cover:</p><p>1. Vertex Pharmaceuticals / CRISPR Therapeutics — Casgevy (exagamglogene autotemcel) for sickle cell disease and transfusion-dependent beta thalassemia in children ages 2 and up (FDA approval — label expansion)</p><p>2. Roche / Genentech — divarasib for KRAS G12C-mutant non-small cell lung cancer (Phase 3)</p><p>3. BridgeBio Pharma / Kyowa Kirin — oral infigratinib for achondroplasia in children (Phase 3, published in NEJM)</p><p><br></p><p>What could this mean for patients? Casgevy in toddlers is the story with the biggest potential ripple effect. Sickle cell disease starts hurting kids in infancy, so treating a 2-year-old before repeated strokes and organ damage sets in could redefine what growing up with sickle cell looks like. It's also a proof point that CRISPR-based cures can be delivered safely in very young children — a green light for other pediatric gene-editing programs in development.</p><p><br></p><p>Part 2 drops Thursday morning. Subscribe at TrialBreaks.com.</p><p><br></p><p>#biomedicine #clinicaltrials #science #CRISPR #genetherapy #sicklecell #lungcancer #KRAS #achondroplasia #oncology #rarediseases #pediatrics #hematology #NEJM #immunotherapy</p>
July 2, 2026
Last Week in Biomedicine | June 22–26 | Part 2 of 2: Thyroid Eye Disease, ADHD + Anxiety, Skyrizi Kids
<p>Part 2 covers a new drug for the bulging-eye autoimmune disease, the first Phase 3 ADHD trial designed for patients who also have anxiety, and a major pediatric expansion for a top-selling psoriasis biologic. In Part 2 we cover:</p><p><br></p><p>4. Viridian Therapeutics — Lumvoa (veligrotug) for thyroid eye disease, active and chronic (FDA approval)</p><p>5. Otsuka Pharmaceutical — centanafadine for adult ADHD with comorbid anxiety (Phase 3b)</p><p>6. AbbVie — Skyrizi (risankizumab) for pediatric plaque psoriasis and psoriatic arthritis (FDA approval)</p><p><br></p><p>The biggest story in Part 2: Lumvoa is only the second IGF-1 receptor antibody ever approved for thyroid eye disease, but it has a much broader label than its predecessor — covering both the active early form and the chronic long-standing form that affects far more patients. For people who've lived with bulging eyes and double vision for years and were told nothing could help, this approval is genuinely new ground.</p><p><br></p><p>Catch Part 1 if you missed it. Subscribe at TrialBreaks.com.</p><p><br></p><p>#biomedicine #clinicaltrials #science #ophthalmology #thyroideyedisease #ADHD #anxiety #mentalhealth #dermatology #psoriasis #pediatrics #immunology #FDAapproval #autoimmune #IL23</p><p><br></p>
17 total episodes available
Deep-dive analytics for Last Week in Biomedicine
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Last Week in Biomedicine?
- How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
No, this podcast does not typically feature guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.